Omalizumab biosimilar - Mycenax Biotech

Drug Profile

Omalizumab biosimilar - Mycenax Biotech

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mycenax Biotech
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Allergic asthma; Urticaria

Most Recent Events

  • 09 Aug 2017 Preclinical trials in Allergic asthma in Taiwan (Parenteral) before August 2017 (Mycenax Biotech pipeline, August 2017)
  • 09 Aug 2017 Preclinical trials in Urticaria in Taiwan (Parenteral) before August 2017 (Mycenax Biotech pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top